10 April 2025

ELISAs for complement-dependent cytotoxicity testing

Explore QuidelOrtho ELISAs and high-quality reagents for biological therapeutics research through complement-dependent cytotoxicity testing. Where immune activation meets therapeutic precision.


The complement system is a network of 50+ individual proteins, protein complexes and fragments that drive a host’s innate immune response via three main pathways: alternative, classical and lectin. Complement-dependent cytotoxicity (CDC) is the natural mechanism by which therapeutics, most often humanized antibodies but also other non-antibody proteins and peptides, activate the complement system. This ultimately leads to the formation of the membrane attack complex (MAC), clearance of non-host materials and additional immune system response.

Biological therapeutics can induce CDC. This can be either a negative or positive outcome depending on the desired therapeutic goal:

  • Negative CDC: Unregulated complement activation contributes to host autoimmune response and downstream adverse effects
  • Positive CDC: Complement activation amplifies therapeutic target effector mechanisms

Measuring CDC is important for assessing overall biocompatibility, requiring several parameters to accurately evaluate the potential contribution of the complement system.

QuidelOrtho specialty products group (SPG) offers a variety of assays and reagents for CDC assays

CDC assay materialProduct descriptionCatalog #
Complement source and activatorsNormal human serum (NHS) ▪ Source of human complement system proteins specially processed for minimal activationA111 (1.0 mL) A112 (2.5 mL) A113 (5.0 mL)
Cobra venom factor (CVF)  ▪ Purified snake protein that activates the complement systemA600 A601 (recombinant)
Assay kits to detect complement activationMicroVue CH50 EIAA018
MicroVue Ba EIAA034
MicroVue Bb EIAA027
MicroVue C3a Plus EIAA032
MicroVue iC3b EIAA006
MicroVue C4a EIAA036
MicroVue C4d EIAA008
MicroVue C5a EIAA025
MicroVue sC5b-9 Plus EIAA029
MicroVue Complement Multiplex
▪ Multi-analyte enzyme immunoassay (EIA) format multiplex to detect multiple complement proteins
Varies
Complement EIA kits can be used to detect general and pathway-specific activation during CDC assays. Individual experimental needs may vary.

▪ General activation: C3a EIA, iC3b EIA, C5a EIA, sC5b-9 EIA
▪ Classical/lectin pathway: CH50 EIA, C4a EIA, C4d EIA  
▪ Alternative pathway: Ba EIA, Bb EIA

Materials needed for CDC assays that are not provided by QuidelOrtho include:

  • Biologic therapeutic (antibody/protein/peptide)
  • Therapeutic target (e.g., target cells)

Assay parameters

The following assay parameters are provided as guidelines only and are not intended to be inclusive of all possible variations of the experiment.

Terms and definitions:

  • Biologic therapeutic: Therapeutic antibody, peptide or protein
  • Biologic control: Non-specific and non-therapeutic antibody, peptide or protein
  • Therapeutic target: Intended target of the biologic therapeutic (e.g., cells)

Control assays

The following reagent and assay suggestions may act as controls for proper materials performance.

MaterialsDescriptionProducts needed
Biologic therapeutic + NHS(–) Control: Evaluate if biologic therapeutic aggregates and activates complement while in soluble form.NHS: Complement source

CVF: Complement activator

EIA kits: Complement protein detection (see product list section for specific kit recommendations)
Biologic control + NHS(–) Control: Evaluate if non-therapeutic biological control activates complement.
Therapeutic target + NHS(–) Control: Evaluate if therapeutic targets activate complement (ex. surface carbohydrate initiates the lectin pathway).
CVF + NHS(+) Control: Provides data range for comparison if complement is activated in the CDC assay.

CDC assays

The CDC assay combines the biologic therapeutic and its target to evaluate complement activation.

MaterialsDescriptionProducts needed
Biologic therapeutic + Therapeutic target + NHSEvaluate if the combination of the therapeutic biologic and target activates the complement system, leading to CDC. Variations of dilutions, concentrations and incubation times should be considered.NHS: Complement source

EIA kits: Complement protein detection (see product list section for specific kit recommendations)

QuidelOrtho SPG offers dozens of products for measuring and studying the complement system, including ELISAs, multiplex, antibodies, proteins, serum, depleted sera and reagents.

ELISAs for complement-dependent cytotoxicity testing

Related articles

Newsletter for researchers

We gladly support you by keeping you updated on our latest products and the developments around our services.

we Connect you
Need help? Contact our technical support
Contact